ROP.SW

Healthcare Drug Manufacturers - General

Roche Holding AG

CHF 349.80

+2.30 +0.66% today

Price History

Not enough data

Key Stats

Market Cap

278.71B

Avg Volume

888,628

P/E (TTM)

22.82

EPS

CHF 15.33

52W High

CHF 375.80

52W Low

CHF 258.20

Div. Yield

2.8%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

15.98

P/B Ratio

8.53

P/S Ratio

4.43

EV/EBITDA

12.75

EV/Revenue

4.85

PEG Ratio

1.58

Margins

Gross Margin 74.2%

Operating Margin 36.2%

Net Margin 19.6%

EBITDA Margin 38.1%

Growth & Returns

Revenue Growth (YoY)

(1.2%)

Earnings Growth (YoY)

(7.7%)

Earnings Growth (QoQ)

(7.3%)

Return on Equity

38.1%

Return on Assets

13.5%

Liquidity & Leverage

Current Ratio

1.23

Quick Ratio

0.80

Debt / Equity

0.91

Total Cash

9.73B

Total Debt

33.31B

About

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.